Although cox-2 is a selective target of celecoxib and its expression has been reported in several cancers including colorectal, breast, pulmonary, prostate and malignant melanoma [31–33], many celecoxib anti-tumor effects are independent of cox-2. This evidence concerns the gene PTGS2 and neoplasm.